Generated Narrative: Composition 236951 version: 107; Last updated: 2025-10-07 17:12:54+0000; Language: en Profile: SummaryOfFindings url: https://fevir.net/resources/Composition/236951 identifier: FEvIR Object Identifier/236951, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-summary-of-findings-85394-85798 status: Final type: Summary of Findings date: 2025-10-07 17:12:54+0000 author: Qiukui Hao title: SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes custodian: Computable Publishing LLC relatesTo type: Part Of target: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report) relatesTo type: Part Of target: ComparativeEvidenceSynthesisReport: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-comparative-evidence-report-85394-85798) relatesTo type: Cite As target: SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Composition Resource]. Contributors: Qiukui Hao [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236951. Revised 2025-10-07. Available at: https://fevir.net/resources/Composition/236951. Computable resource at: https://fevir.net/resources/Composition/236951#json.
SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes
ComparativeEvidenceSynthesisReport: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Composition Resource]. Contributors: Qiukui Hao [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236951. Revised 2025-10-07. Available at: https://fevir.net/resources/Composition/236951. Computable resource at: https://fevir.net/resources/Composition/236951#json.
Outcome
Sample Size
Result Without Treatment
Result With Treatment (Observed)
Result with intervention alone (calculated)
result with intervention with calculated value derived from the control group and effect estimate
Result With Treatment (Calculated)
Effect Estimate
Certainty of Evidence
What this means
[No data.]
Summary of findings entry for a single outcome
All-cause mortality
2 studies, 1282 participants
MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
0.24
MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
0.22
MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
Risk Difference -2.3% ( -4% to -0.4%); Odds Ratio 0.88 ( 0.79 to 0.98)
Moderate certainty
SGLT2 inhibitors probably reduce the risk of all cause mortality compared with GLP-1 receptor agonists.
OutcomeDefinition: Cardiovascular mortality
Cardiovascular mortality
1 studies, 463 participants
MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
0.16
MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
0.15
MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
Risk Difference -0.5% ( -2.2% to 1.2%); Odds Ratio 0.96 ( 0.84 to 1.09)
There probably be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists.
OutcomeDefinition: Nonfatal myocardial infarction
Nonfatal myocardial infarction
MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
0.18
MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
0.17
MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes
17%
Risk Difference -0.7% ( -2.4% to 1.1%); Odds Ratio 0.95 ( 0.84 to 1.08)
There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of nonfatal myocardial infarction.
Nonfatal stroke
MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
0.19
MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes
Risk Difference 2.7% ( 0.4% to 5.3%); Odds Ratio 1.2 ( 1.03 to 1.41)
SGLT2 inhibitors probably increase the risk of nonfatal stroke compared with GLP-1 receptor agonists.
OutcomeDefinition: End-stage kidney disease
End-stage kidney disease
MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
0.12
MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
0.11
MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes
Risk Difference -1% ( -3.4% to 2%); Odds Ratio 0.91 ( 0.69 to 1.2)
Heart failure
[No sample size data found.]
MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes
High certainty
SGLT2 inhibitors reduce the risk of heart failure compared with GLP-1 receptor agonists.
OutcomeDefinition: Diabetic ketoacidosis
Diabetic ketoacidosis
MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes
0.2%
Risk Difference 0.1% ( 0% to 0.3%); Odds Ratio 1.71 ( 0.79 to 3.69)
There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of diabetic ketoacidosis.
OutcomeDefinition: Serious hyperglycaemia
Serious hyperglycaemia
MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
0.01
MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
1.5%
Risk Difference 0.5% ( -0.2% to 1.9%); Odds Ratio 1.48 ( 0.75 to 2.93)
There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of serious hyperglycaemia.
Genital infection
MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
0.05
MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
0.21
MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes
Risk Difference 15.8% ( 6.4% to 29.9%); Odds Ratio 5 ( 2.45 to 10.2)
SGLT2 inhibitors increase the risk of genital infection compared with GLP-1 receptor agonists.
OutcomeDefinition: Severe gastrointestinal events
Severe gastrointestinal events
7 studies, 24638 participants
MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
0.04
MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
0.1
MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes
Risk Difference 5.8% ( 0.9% to 14.2%); Odds Ratio 2.46 ( 1.22 to 4.97)
Very low certainty
GLP-1 receptor agonists may increase the risk of severe gastrointestinal events compared with SGLT2 inhibitors.
OutcomeDefinition: Health-related quality of life
Health-related quality of life
MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
[Not a proportion.]
MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes
Standardized Mean Difference 0.01 ( -0.19 to 0.2)
Low certainty
There may be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on health-related quality of life.
Body weight
2 studies, 1139 participants
MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes
Mean Difference -0.47 Kg ( -0.09 Kg to -0.85 Kg)
SGLT2 inhibitors probably reduce body weight compared with GLP-1 receptor agonists.